SHR-A1912

SHR-A1912 is a novel antibody-drug conjugate (ADC) developed in China that targets CD79b, a component of the B-cell antigen receptor complex highly expressed on B-cell non-Hodgkin lymphomas. The drug consists of an anti-CD79b monoclonal antibody conjugated to a DNA topoisomerase I inhibitor as its cytotoxic payload. This mechanism differs from other CD79b-targeted ADCs such as polatuzumab vedotin, which uses a microtubule inhibitor payload. SHR-A1912 is designed for the treatment of relapsed or refractory B-cell lymphomas and has shown promising anti-tumor activity and manageable safety in early-phase clinical trials. It has received FDA fast track designation for relapsed/refractory diffuse large B-cell lymphoma (DLBCL)[2][5][7].